Halüsinojen Etkili Maddeler

Authors

Melike Aydoğdu
https://orcid.org/0000-0002-6324-0234
Ömer Demir
https://orcid.org/0000-0002-9145-1549

Synopsis

This chapter examines hallucinogens, which are psychoactive substances that significantly alter perception, mood, and cognitive processes. Hallucinogens are classified based on their pharmacological mechanisms of action and chemical structures into classic hallucinogens, entactogens, dissociative anesthetics, atypical hallucinogens, delirants, and new designer synthetic hallucinogens. The text details the general background, history, pharmacokinetic and pharmacodynamic properties, analytical methods, and forensic toxicological aspects of Lysergic Acid Diethylamide (LSD), mescaline, psilocybin, phencyclidine (PCP), N,N-Dimethyltryptamine (DMT), bufotenine, ketamine, salvinorin A, Datura stramonium, and novel synthetic derivatives. LSD is the most potent known hallucinogen acting as a serotonin 2A receptor agonist, whereas mescaline is the oldest known phenethylamine-structured hallucinogen derived from the peyote cactus. Psilocybin, found in mushrooms, acts as a prodrug converted into psilocin in the body. PCP and ketamine produce dissociative effects as NMDA antagonists. DMT and bufotenine are tryptamine-derived compounds. Salvinorin A acts as a kappa opioid receptor agonist, and Datura stramonium is a plant exhibiting anticholinergic effects. Although most of these substances carry low physical dependence and physiological toxicity risks, they can cause panic reactions, flashbacks, acute psychosis, and, in high doses, fatal poisonings.

References

Nichols DE. Hallucinogens. Pharmacology and Therapeutics. 2004;101(2): 131–181. doi:10.1016/j.pharmthera.2003.11.002

Araújo AM, Carvalho F, Bastos M de L, et al. The hallucinogenic world of tryptamines: an updated review. Archives of Toxicology. Springer Berlin Heidelberg; 2015;89(8): 1151–1173. doi:10.1007/s00204-015-1513-x

Garcia-Romeu A, Kersgaard B, Addy PH. Clinical applications of hallucinogens: A review. Experimental and Clinical Psychopharmacology. 2016;24(4): 229–268. doi:10.1037/pha0000084

Luethi D, Liechti ME. Designer drugs: mechanism of action and adverse effects. [Online] Archives of Toxicology. Springer Berlin Heidelberg; 2020. 1085–1133 p. doi:10.1007/s00204-020-02693-7

Araújo AM, Carvalho F, Bastos M de L, et al. The hallucinogenic world of tryptamines: an updated review. Archives of Toxicology. Springer Berlin Heidelberg; 2015;89(8): 1151–1173. doi:10.1007/s00204-015-1513-x

Lysergic acid diethylamide. [Online] http://www.chemspider.com/Chemical-Structure.5558.html

Hallucinogenic mushrooms drug profile. [Online] https://www.emcdda.europa.eu/publications/drug-profiles/hallucinogenic-mushrooms_en

EMCDDA. Lysergide (LSD) drug profile. [Online] https://www.emcdda.europa.eu/publications/drug-profiles/lsd_en

Marinho PA, Leite EMA. Quantification of LSD in illicit samples by high performance liquid chromatography. Brazilian Journal of Pharmaceutical Sciences. 2010;46(4): 695–703. doi:10.1590/S1984-82502010000400011

Dolder PC, Schmid Y, Steuer AE, et al. Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects. Clinical Pharmacokinetics. Springer International Publishing; 2017;56(10): 1219–1230. doi:10.1007/s40262-017-0513-9

Libânio Osório Marta RF. Metabolism of lysergic acid diethylamide (LSD): an update. Drug Metabolism Reviews. Taylor & Francis; 2019;51(3): 378–387. doi:10.1080/03602532.2019.1638931

Klock JC, Boerner U, Becker CE. Coma, hyperthermia and bleeding associated with massive LSD overdose. A report of eight cases. West J Med. 1974;120(3): 183–188. http://www.ncbi.nlm.nih.gov/pubmed/4816396

Nichols DE, Grob CS. Is LSD toxic? Forensic Science International. 2018;284: 141–145. doi:10.1016/j.forsciint.2018.01.006

Grobosch T, Lemm-Ahlers U. Immunoassay screening of lysergic acid diethylamide (LSD) and its confirmation by HPLC and fluorescence detection following LSD ImmunElute extraction. Journal of Analytical Toxicology. 2002;26(3): 181–186. doi:10.1093/jat/26.3.181

Gaulier J michel, Maublanc J, Lamballais F, et al. LSD in pubic hair in a fatality. Forensic Science International. 2012;218(1–3): 25–27. doi:10.1016/j.forsciint.2011.10.021

Bruhn JG, De Smet PAGM, El-Seedi HR, et al. Mescaline use for 5700 years. The Lancet. 2002;359(25): 2002–2002.

Meuninck J. Poisonous and Psychoactive Plants.. 1st ed. Globe Pequot Press. Morris Book Publishing; 2014.

Dinis-Oliveira RJ, Pereira CL, da Silva DD. Pharmacokinetic and Pharmacodynamic Aspects of Peyote and Mescaline: Clinical and Forensic Repercussions. Current Molecular Pharmacology. 2018;12(3): 184–194. doi:10.2174/1874467211666181010154139

Cassels BK, Sáez-Briones P. Dark Classics in Chemical Neuroscience: Mescaline. ACS Chemical Neuroscience. 2018;9(10): 2448–2458. doi:10.1021/acschemneuro.8b00215

Dinis-Oliveira RJ, Pereira CL, da Silva DD, et al. Urine mescaline screening with a biochip array immunoassay and quantification by gas chromatography-mass spectrometry. The Lancet. 2020;37(1): 372–375. doi:10.1086/710634

Longo CM, Musah RA. An Efficient Ambient Ionization Mass Spectrometric Approach to Detection and Quantification of the Mescaline Content of Commonly Abused Cacti from the Echinopsis Genus. Journal of Forensic Sciences. 2020;65(1): 61–66. doi:10.1111/1556-4029.14134

Dinis-Oliveira RJ. Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance. Drug Metabolism Reviews. 2017;49(1): 84–91. doi:10.1080/03602532.2016.1278228

Psilocybine. [Online] https://pubchem.ncbi.nlm.nih.gov/compound/Psilocybine

Dasgupta A. Abuse of magic mushroom, peyote cactus, LSD, khat, and volatiles. Critical Issues in Alcohol and Drugs of Abuse Testing. Second Edi. Elsevier Inc.; 2019. p. 477–494. doi:10.1016/B978-0-12-815607-0.00033-2

Gartz J. Magic Mushrooms Around the World A Scientific Journey Across Cultures and Time. 1997; 133.

Martin R, Schürenkamp J, Pfeiffer H, et al. A validated method for quantitation of psilocin in plasma by LC-MS/MS and study of stability. International Journal of Legal Medicine. 2012;126(6): 845–849. doi:10.1007/s00414-011-0652-8

Tiscione NB, Miller MI. Psilocin identified in a DUID investigation. Journal of Analytical Toxicology. 2006;30(5): 342–345. doi:10.1093/jat/30.5.342

UNODC. Phencyclidine-type substances. [Online] https://www.unodc.org/LSS/SubstanceGroup/Details/6bf165ed-82e7-47e0-9eaa-daacc42d99cd

Bertron JL, Seto M, Lindsley CW. DARK Classics in Chemical Neuroscience: Phencyclidine (PCP). ACS Chemical Neuroscience. 2018;9(10): 2459–2474. doi:10.1021/acschemneuro.8b00266

Dugan S, Bogema S, Schwartz RW, et al. Stability of drugs of abuse in urine samples stored at -20 degrees C. J Anal Toxicol. 1994;18(7): 391–396. http://www.ncbi.nlm.nih.gov/pubmed/7861752

Rengarajan A, Mullins ME. How often do false-positive phencyclidine urine screens occur with use of common medications? Clinical Toxicology. Clin Toxicol (Phila); 2013;51(6): 493–496. doi:10.3109/15563650.2013.801982

Budd R, Liu Y. Phencyclidine concentrations in postmortem body fluids and tissues. Journal of toxicology. Clinical Toxicology. 1982;19(8): 843–850.

Misra AL, Pontani RB, Bartolomeo J. Persistence of phencyclidine (PCP) and metabolites in brain and adipose tissue and implications for long-lasting behavioural effects. Res Commun Chem Pathol Pharmacol. 1979;24(3): 431–445. http://www.ncbi.nlm.nih.gov/pubmed/451333

Dimetiltriptamin. [Online] https://eksisozluk.com/dimetiltriptamin--116693

Dean JG. Indolethylamine-N-methyltransferase polymorphisms: Genetic and biochemical approaches for study of endogenous N, N,-dimethyltryptamine. Frontiers in Neuroscience. 2018;12(APR). doi:10.3389/fnins.2018.00232

Vitale AA, Pomilio AB, Cañellas CO, et al. In vivo long-term kinetics of radiolabeled N,N-dimethyltryptamine and tryptamine. Journal of Nuclear Medicine. 2011;52(6): 970–977. doi:10.2967/jnumed.110.083246

Santos RG dos, Bouso JC, Hallak JEC. Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies. Therapeutic Advances in Psychopharmacology Review. 2017;7(4): 141–157. doi:://doi.org/10.1177/2045125316689030 DOI: 10.1177/ https://doi.org/10.1177/2045125

Cameron LP, Olson DE. Dark Classics in Chemical Neuroscience: N, N-Dimethyltryptamine (DMT). ACS Chemical Neuroscience. 2018;9(10): 2344–2357. doi:10.1021/acschemneuro.8b00101

Effects of Dimethyltryptamine in Healthy Subjects (DMT). [Online] https://clinicaltrials.gov/ct2/show/record/NCT04353024

Sassano-Higgins S, Baron D, Juarez G, et al. A Review of Ketamine Abuse and Diversion. Depression and Anxiety. 2016;33(8): 718–727. doi:10.1002/da.22536

Grant IS, Nimmo WS, Clements JA. Pharmacokinetics and analgesic effects of I.M. and oral ketamine. British Journal of Anaesthesia. British Journal of Anaesthesia; 1981;53(8): 805–810. doi:10.1093/bja/53.8.805

Grant IS, Nimmo WS, Mcnicol LR, et al. Ketamine disposition in children and adults. British Journal of Anaesthesia. British Journal of Anaesthesia; 1983;55(11): 1107–1111. doi:10.1093/bja/55.11.1107

Hernández-Alvarado RB, Madariaga-Mazón A, Ortega A, et al. DARK Classics in Chemical Neuroscience: Salvinorin A. ACS Chemical Neuroscience. 2020;11(23): 3979–3992. doi:10.1021/acschemneuro.0c00608

Turner DM. Salvinorin - The Psychedelic Essence of Salvia Divinorum. Essence. 2004; 1–42.

Roach JJ, Shenvi RA. A review of salvinorin analogs and their kappa-opioid receptor activity. Bioorganic and Medicinal Chemistry Letters. 2018;28(9): 1436–1445. doi:10.1016/j.bmcl.2018.03.029

Socała K, Doboszewska U, Wlaź P. Salvinorin a does not affect seizure threshold in mice. Molecules. 2020;25(5). doi:10.3390/molecules25051204

Medana C, Massolino C, Pazzi M, et al. Determination of salvinorins and divinatorins in Salvia divinorum leaves by liquid chromatography/multistage mass spectrometry. Rapid Commun Mass Spectrom. 2006;20(2): 131–136.

Barnes BB, Snow NH. Analysis of Salvinorin A in plants, water, and urine using solid-phase microextraction-comprehensive two-dimensional gas chromatography-time of flight mass spectrometry. J Chromatogr A. 2012;1226: 110–115. doi:10.1016/j.chroma.2011.09.056

El-Khoury J, Baroud E. Case series: Salvia divinorum as a potential addictive hallucinogen. American Journal on Addictions. 2018;27(3): 163–165. doi:10.1111/ajad.12715

Gaire BP, Subedi L. A review on the pharmacological and toxicological aspects of Datura stramonium L. Journal of Chinese Integrative Medicine. Journal of Integrative Medicine Editorial Office. E-edition published by Elsevier (Singapore) Pte Ltd. All rights reserved.; 2013;11(2): 73–79. doi:10.3736/jintegrmed2013016

Amini M, Khosrojerdi H, Afshari R. Acute Datura Stramonium poisoning in East of Iran - a case series. Avicenna journal of phytomedicine. 2012;2(2): 86–89. doi:10.22038/ajp.2012.37

Suzuki J, Dekker MA, Valenti ES, et al. Toxicities Associated With NBOMe Ingestion-A Novel Class of Potent Hallucinogens: A Review of the Literature. Psychosomatics. Elsevier; 2015;56(2): 129–139. doi:10.1016/j.psym.2014.11.002

Altuncı YA, Aydoğdu M, Açıkgöz E, et al. New Psychoactive Substance 5-MeO-MIPT In vivo Acute Toxicity and Hystotoxicological Study. Balkan Medical Journal. 2020; doi:10.4274/balkanmedj.galenos. 2020.2019.11.68

Published

November 4, 2021

License

License